MEDROXYPROGESTERONE ACETATE by Cipla is clinical pharmacology table 1. Approved for secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such and 1 more indications. First approved in 2019.
Drug data last refreshed 23h ago
CLINICAL PHARMACOLOGY Table 1. Mean (SD) Pharmacokinetic Parameters for Medroxyprogesterone Acetate (MPA) Tablet Strength C max (ng/mL) T max (h) AUC 0-(inf) (ng-h/mL) t 1/2 (h) Vd/f (L) CL/f (mL/min) Single Dose 2 x 10 mg 1.01 (0.599) 2.65 (1.41) 6.95 (3.39) 12.1 (3.49) 78024 (47220) 64110 (42662)…
Worked on MEDROXYPROGESTERONE ACETATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate